Evidence map›Paper›PMID 37456806›Full record

ArticleJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques2023

COVID-19 mRNA vaccination is associated with IgA nephropathy: an analysis of the Japanese adverse drug event report database.

Hiroka Nakao, Takenao Koseki, Koki Kato, Shigeki Yamada, Naotake Tsuboi, Kazuo Takahashi, Tomohiro Mizuno

Open access · diamondAbstract read
In one paragraph

Article in Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Hiroka NakaoDepartment of Biomedical Molecular Sciences, School of Medicine, Fujita Health University, Toyoake, Japan.
Takenao KosekiDepartment of Pharmacotherapeutics and Informatics, School of Medicine, Fujita Health University, Toyoake, Japan.
Koki KatoDepartment of Pharmacotherapeutics and Informatics, School of Medicine, Fujita Health University, Toyoake, Japan.
Shigeki YamadaDepartment of Pharmacotherapeutics and Informatics, School of Medicine, Fujita Health University, Toyoake, Japan.
Naotake TsuboiDepartment of Nephrology, School of Medicine, Fujita Health University, Toyoake, Japan.
Kazuo TakahashiDepartment of Biomedical Molecular Sciences, School of Medicine, Fujita Health University, Toyoake, Japan.
Tomohiro MizunoDepartment of Pharmacotherapeutics and Informatics, School of Medicine, Fujita Health University, Toyoake, Japan.
Institute for Molecular Science · JPFujita Health University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Drug-Related Side Effects and Adverse ReactionsGlomerulonephritis, IGAAdverse Drug Reaction Reporting SystemsCOVID-19 VaccinesEast Asian PeopleHumansmRNA VaccinesSARS-CoV-2VaccinationCOVID-19 VaccinesmRNA VaccinesCOVID-19IgA nephropathyJapanese adverse drug event reportmRNA vaccinereporting odds ratio

Identifiers

PMID37456806
PMCPMC10348063
OpenAlexW4382775888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.